BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

162 related articles for article (PubMed ID: 35871993)

  • 21. Comparison of prostate cancer detection rates in patients undergoing MRI/TRUS fusion prostate biopsy with two different software-based systems.
    Hanske J; Risse Y; Roghmann F; Pucheril D; Berg S; Tully KH; von Landenberg N; Wald J; Noldus J; Brock M
    Prostate; 2022 Feb; 82(2):227-234. PubMed ID: 34734428
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Prebiopsy Biparametric Magnetic Resonance Imaging Combined with Prostate-specific Antigen Density in Detecting and Ruling out Gleason 7-10 Prostate Cancer in Biopsy-naïve Men.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Jakobsen H; Thomsen HS
    Eur Urol Oncol; 2019 May; 2(3):311-319. PubMed ID: 31200846
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A multicentre randomised controlled trial assessing whether MRI-targeted biopsy is non-inferior to standard transrectal ultrasound guided biopsy for the diagnosis of clinically significant prostate cancer in men without prior biopsy: a study protocol.
    Kasivisvanathan V; Jichi F; Klotz L; Villers A; Taneja SS; Punwani S; Freeman A; Emberton M; Moore CM
    BMJ Open; 2017 Oct; 7(10):e017863. PubMed ID: 29025845
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Three-Tesla magnetic resonance-guided prostate biopsy in men with increased prostate-specific antigen and repeated, negative, random, systematic, transrectal ultrasound biopsies: detection of clinically significant prostate cancers.
    Hoeks CM; Schouten MG; Bomers JG; Hoogendoorn SP; Hulsbergen-van de Kaa CA; Hambrock T; Vergunst H; Sedelaar JP; Fütterer JJ; Barentsz JO
    Eur Urol; 2012 Nov; 62(5):902-9. PubMed ID: 22325447
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Prediction of High-grade Prostate Cancer Following Multiparametric Magnetic Resonance Imaging: Improving the Rotterdam European Randomized Study of Screening for Prostate Cancer Risk Calculators.
    Alberts AR; Roobol MJ; Verbeek JFM; Schoots IG; Chiu PK; Osses DF; Tijsterman JD; Beerlage HP; Mannaerts CK; Schimmöller L; Albers P; Arsov C
    Eur Urol; 2019 Feb; 75(2):310-318. PubMed ID: 30082150
    [TBL] [Abstract][Full Text] [Related]  

  • 26. MRI to guide biopsies or avoid biopsies?
    Winoker JS; Pinto PA; Rastinehad AR
    Curr Opin Urol; 2018 Nov; 28(6):522-528. PubMed ID: 30239414
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Value of targeted prostate biopsy using magnetic resonance-ultrasound fusion in men with prior negative biopsy and elevated prostate-specific antigen.
    Sonn GA; Chang E; Natarajan S; Margolis DJ; Macairan M; Lieu P; Huang J; Dorey FJ; Reiter RE; Marks LS
    Eur Urol; 2014 Apr; 65(4):809-15. PubMed ID: 23523537
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Assessment of the Diagnostic Accuracy of Biparametric Magnetic Resonance Imaging for Prostate Cancer in Biopsy-Naive Men: The Biparametric MRI for Detection of Prostate Cancer (BIDOC) Study.
    Boesen L; Nørgaard N; Løgager V; Balslev I; Bisbjerg R; Thestrup KC; Winther MD; Jakobsen H; Thomsen HS
    JAMA Netw Open; 2018 Jun; 1(2):e180219. PubMed ID: 30646066
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Why Does Magnetic Resonance Imaging-Targeted Biopsy Miss Clinically Significant Cancer?
    Williams C; Ahdoot M; Daneshvar MA; Hague C; Wilbur AR; Gomella PT; Shih J; Khondakar N; Yerram N; Mehralivand S; Gurram S; Siddiqui M; Pinsky P; Parnes H; Merino M; Wood B; Turkbey B; Pinto PA
    J Urol; 2022 Jan; 207(1):95-107. PubMed ID: 34433302
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prospective study of diagnostic accuracy comparing prostate cancer detection by transrectal ultrasound-guided biopsy versus magnetic resonance (MR) imaging with subsequent MR-guided biopsy in men without previous prostate biopsies.
    Pokorny MR; de Rooij M; Duncan E; Schröder FH; Parkinson R; Barentsz JO; Thompson LC
    Eur Urol; 2014 Jul; 66(1):22-9. PubMed ID: 24666839
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The GÖTEBORG prostate cancer screening 2 trial: a prospective, randomised, population-based prostate cancer screening trial with prostate-specific antigen testing followed by magnetic resonance imaging of the prostate.
    Kohestani K; Månsson M; Arnsrud Godtman R; Stranne J; Wallström J; Carlsson S; Hellström M; Hugosson J
    Scand J Urol; 2021 Apr; 55(2):116-124. PubMed ID: 33612068
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Structured Population-based Prostate-specific Antigen Screening for Prostate Cancer: The European Association of Urology Position in 2019.
    Gandaglia G; Albers P; Abrahamsson PA; Briganti A; Catto JWF; Chapple CR; Montorsi F; Mottet N; Roobol MJ; Sønksen J; Wirth M; van Poppel H
    Eur Urol; 2019 Aug; 76(2):142-150. PubMed ID: 31092338
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Clinical and imaging tools in the early diagnosis of prostate cancer, a review.
    De Visschere P; Oosterlinck W; De Meerleer G; Villeirs G
    JBR-BTR; 2010; 93(2):62-70. PubMed ID: 20524513
    [TBL] [Abstract][Full Text] [Related]  

  • 34. The Effectiveness of Prostate Imaging and Reporting and Data System Version 2 in the Diagnosis of Prostate Cancer with Screening Parameters Correlation.
    Arik ŞB; Güvenir D; Bozlar U; Taşar M; Turgut B
    Arch Esp Urol; 2022 Jun; 75(5):416-422. PubMed ID: 35983812
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [MRI of the prostate].
    Nörenberg D; Solyanik O; Schlenker B; Magistro G; Ertl-Wagner B; Clevert DA; Stief C; Reiser MF; D'Anastasi M
    Urologe A; 2017 May; 56(5):665-677. PubMed ID: 28424829
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Multiparametric MRI to improve detection of prostate cancer compared with transrectal ultrasound-guided prostate biopsy alone: the PROMIS study.
    Brown LC; Ahmed HU; Faria R; El-Shater Bosaily A; Gabe R; Kaplan RS; Parmar M; Collaco-Moraes Y; Ward K; Hindley RG; Freeman A; Kirkham A; Oldroyd R; Parker C; Bott S; Burns-Cox N; Dudderidge T; Ghei M; Henderson A; Persad R; Rosario DJ; Shergill I; Winkler M; Soares M; Spackman E; Sculpher M; Emberton M
    Health Technol Assess; 2018 Jul; 22(39):1-176. PubMed ID: 30040065
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Cost-effectiveness of multiparametric magnetic resonance imaging and MRI-guided biopsy in a population-based prostate cancer screening setting using a micro-simulation model.
    Getaneh AM; Heijnsdijk EA; de Koning HJ
    Cancer Med; 2021 Jun; 10(12):4046-4053. PubMed ID: 33991077
    [TBL] [Abstract][Full Text] [Related]  

  • 38. High cancer detection rate using cognitive fusion - targeted transperineal prostate biopsies.
    Dekalo S; Matzkin H; Mabjeesh NJ
    Int Braz J Urol; 2017; 43(4):600-606. PubMed ID: 28783264
    [TBL] [Abstract][Full Text] [Related]  

  • 39. A Pragmatic Approach to Prostate Cancer Screening.
    Tosoian JJ; Penson DF; Chinnaiyan AM
    JAMA; 2024 May; 331(17):1448-1450. PubMed ID: 38581253
    [No Abstract]   [Full Text] [Related]  

  • 40. Clinical implementation of pre-biopsy magnetic resonance imaging pathways for the diagnosis of prostate cancer.
    Israël B; Immerzeel J; van der Leest M; Hannink G; Zámecnik P; Bomers J; Schoots IG; van Basten JP; Debruyne F; van Oort I; Sedelaar M; Barentsz J
    BJU Int; 2022 Apr; 129(4):480-490. PubMed ID: 34358388
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.